MonoSol Rx, BiondVax form partnership to develop oral-film vaccine delivery
WARREN, N.J. — A company developing drug-delivery technology based on films inserted into the mouth and a company developing a flu vaccine have entered a deal to combine their products.
MonoSol Rx on Wednesday announced that it had entered a partnership with Israel-based BiondVax to combine MonoSol's PharmFilm technology with BiondVax's universal flu vaccine, M-001, to create a way to deliver vaccines without needles. MonoSol Rx co-president and CEO A. Mark Schobel said using his company's technology for vaccinations could lead to increased acceptance of flu vaccination.
"We have believed for some time in the significant advantages PharmFilm can offer in the delivery of a broad range of vaccines," Schobel said. "We view this partnership with BiondVax as an opportunity to demonstrate the clear advantages our proprietary PharmFilm technology platform offers the vaccine industry."